



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Chernyshev, Olga N.
)	
Avi Ashkenazi <i>et al.</i>)	Art Unit: 1646
)	
Application Serial No. 09/905,075)	Attorney's Docket No. 39780-1618 P2C5
)	
Filed: July 13, 2001)	Customer No. 35489
)	
For: SECRETED AND)	
TRANSMEMBRANE)	
POLYPEPTIDES AND NUCLEIC)	
ACIDS ENCODING THE SAME)	

EXPRESS MAIL LABEL NO. EL 976 544 041 US
Date Mailed: November 9, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MS: RCE
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Supplemental Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

- ☐ a certification as specified in §1.97(e) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.


☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-1618P2C5).**

Respectfully submitted,

By: Leslie A. Mooi
Leslie A. Mooi (Reg. No. 37,047)

Dated: November 9, 2004

HELLER EHRMAN WHITE & McAULIFFE LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 35489



SUPPLEMENTAL FORM PTO-1449

Attorney's Docket No. 39780-1618 P2C5

Application Serial No. 09/905,075

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Avi Ashkenazi *et al.*

Filing Date: July 13, 2001

Group Art Unit: 1646

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	10/1/1996	5,561,053	Crowley	435	69.1	08/05/1994
	2.	06/03/1997	5,635,177	Bennett <i>et al.</i>	424	143.1	04/04/1994
	3.	04/06/1999	5,891,637	Ruppert	435	6	09/15/1997

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation	
							YES	NO
	4.	03/25/1999	WO 99/14327	Botstein <i>et al.</i>				
	5.	03/25/1999	WO 99/14241	Fong <i>et al.</i>				

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)


Examiner Initials	Ref. No.	Title
	6.	De Boer, Willem I., "Expression and Functions of EGF, FGF and TGF β -Growth Factor Family Members and Their Receptors in Invasive Human Transitional-Cell-Carcinoma Cells," <i>Int. J. Cancer</i> , 71: 284-291 (1997).
	7.	Lusson, Vieau D., "cDNA Structure of the Mouse and Rat Subtilisin/Kexin-like PC5: A Candidate Proprotein Convertase Expressed in Endocrine and Nonendocrine Cells," <i>Proc. Natl. Acad. Sci.</i> , 90: 6691-6695 (1993).
	8.	Roebroek, Anton J.M., "Cloning and Functional Expression of Dfurin2, a Subtilisin-like Proprotein Processing Enzyme of <i>Drosophila Melanogaster</i> with Multiple Repeats of a Cysteine Motif," <i>The Journal of Biological Chemistry</i> , 267:(24) 17208-17215 (1992).
	9.	Dayhoff, P_AAB53075, WO200053753-A2, (14-SEP-2000), Ashkenazi A.J., et al.
	10.	Dayhoff, P_AAB61231, WO200100638-A2, (04-JAN-2001), Kirst S.J., et al.
	11.	Dayhoff, P_AAB80212, WO200104311-A1, (18-JAN-200), Ashkenazi A.J., et al.
	12.	Dayhoff, P_AAB68596, WO200105836-A1, (25-JAN-2001), Botstein D., et al.
	13.	Dayhoff, P_AAY83224, WO200021996-A2, (20-APR-2000), Ashkenazi A.J., et al.
	14.	Dayhoff, P_AAB00169, WO200055319-A1,(21-SEP-2000), Ashkenazi A.J., et al.
	15.	Dayhoff, P_AAY05283, WO9914327-A2, (25-MAR-1999), Botstein D., et al.
	16.	Dayhoff, P_AAY13344, WO9914328-A2, (25-MAR-1999), Wood W.I., et al.
	17.	Dayhoff, P_AAY08064, WO9914241-A2, (25-MAR-1999), Fong S., et al.
	18.	Dayhoff, P_AAY88571, WO200015666-A2, (23-MAR-2000), Goddard A., et al.
	19.	Dayhoff, P_AAB61233, WO200100638-A2, (04-JAN-2001), Kirst S.J., et al.
	20.	Dayhoff, P_AAH02894.114, PNAS (2002), Strausberg, R.L., et al.
	21.	Dayhoff, NP_077300.1.
	22.	Dayhoff, P_AAB42711, WO200058473-A2, (05-OCT-200), Shimkets R.A., et al.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).



SUPPLEMENTAL FORM PTO-1449

Attorney's Docket No. 39780-1618 P2C5

Application Serial No. 09/905,075

Applicant(s)

Avi Ashkenazi *et al.*

Filing Date: July 13, 2001

Group Art Unit: 1646

(use several sheets if necessary)

23.	Dayhoff, P_AAY91870, WO200017236-A2, (30-MAR-200), Khodadoust, M.M.
24.	GenBank, P_AAC97409, WO200053753-A2, (05-JAN-2000), Ashkenazi, A.J., et al.
25.	GenBank, P_AAF72371, WO200104311-A1, (22-FEB-2000), Ashkenazi, A.J., et al.
26.	GenBank, P_AAF60360, WO200105836-A1, (20-DEC-1999), Botstein, D., et al.
27.	GenBank, P_AAZ93700, WO200021996-A2, (05-OCT-199), Ashkenazi, A.J., et al.
28.	GenBank,, P_AAA30040, WO200015666-A2, (08-SEP-1999), Goddard, A., et al.
29.	GenBank, P_AAA54089, WO200055319-A1, (02-DEC-1999), Ashkenazi, A.J., et al.
30.	GenBank,, P_AAX28433, WO9914327-A2, (10-SEP-1998), Botstein, D., et al.
31.	GenBank,, P_AAX52213, WO9914328-A2, (16-SEP-199), Wood, W.I., et al.
32.	GenBank, P_AAX37671, WO9914241-A2, (17-SEP-1998), Fong, S., et al.
33.	GenBank, AX076909, WO 0105836-A 21, (25-JAN-2001), Botstein, D., et al.
34.	GenBank, P_AAF29457, WO200100638-A2, (16-JUN-2000), Kirst, S.J., et al.
35.	GenBank, P_AAA08503, WO200017236-A2, (24-SEP-1999), Khodadoust, M.M.
36.	GenBank, P_AAC76920, WO200058473-A2, (31-MAR-200), Shimkets, R.A., et al.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).